Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Double-Blind, 2-Way Crossover Study to Investigate the Effects of JNJ-40411813 on Ketamine-Induced Alterations in Neuropsychiatric Performance

To see complete record on, please visit this link

Id: NCT01101659

Organisation Name: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Overal Status: Completed

Start Date: February 2010

Last Update: April 8, 2014

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Brief Summary: The objective of this study is to investigate whether JNJ-40411813 versus placebo reduces psychosis-like symptoms, induced by infusion of a low dose of ketamine. Effects of JNJ-40411813 on ketamine-induced symptoms will be evaluated about 3 hours after a single oral dose when the concentration of JNJ-40411813 in the blood is at its maximum and up to 24 hours after dose administration to assess the duration of a potential JNJ-40411813 effect.

  • Perceptual Disorders
  • Confusion
  • Schizophrenia

Total execution time in seconds: 0.19627904891968